Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Galapagos, Merck End Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Galapagos, Merck End Alliance

Merck and Galapagos NV have agreed to end their development alliances, and Galapagos has regained worldwide rights for all assets in the programs.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck and Galapagos NV have agreed to end their development alliances, and Galapagos has regained worldwide rights for all assets in the programs. Merck will make a payment of $16.5 million to Galapagos for work completed in 2010. Galapagos has received a total of $28.7 million in upfront and milestone payments from the alliance and has regained worldwide rights to the targets discovered and assays developed from the collaboration.

“Changes in our early discovery strategy have required us to make some challenging decisions,” said Kathleen Metters, senior vice president, External Discovery and Preclinical Sciences, at Merck. “We look forward to investigating alternate opportunities to collaborate with Galapagos in the future.”

“In the alliances with Merck, we have discovered promising targets and developed target discovery assays for diseases with considerable unmet medical needs. Galapagos now owns these valuable assets which can form the basis for future alliances,” said Onno van de Stolpe, chief executive officer of Galapagos. “The work delivered to Merck last year also made a strong contribution to Galapagos’ financial results in 2010.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters